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Although laboratory rodents are a popular species for biomedical research, increasing use has been made of nonhuman primates over the last twenty years or so. In some instances this is probably due to their phylogenetic similarity to man, but it is more likely to be because no other species is suitable for the investigation under consideration. For example, only in simians is it possible to carry out comparative neurovirulence tests on the three strains of poliovirus employed for the manufacture of vaccine. In another field, that of oral pathology, Cohen and his colleagues have made very valuable contributions to the study of dental caries using monkeys of the species Macaca fascicularis. These animals, when maintained on a diet normally used for human consumption, develop lesions closely resembling those seen in man (Cohen & Bowen 1966) .
However, because a species such as this is eminently suitable as a model for one study it does not follow that it will be suitable for other investigations. For example, Shackleton & Mitchell (1975) demonstrated the unsuitability of M. fascicularis as a model for a study of steroid endocrinology of pregnancy, since these monkeys have a very different metabolism from that of man and the great apes.
This presentation has attempted to illustrate some of the more general aspects related to the selection and use of animals for comparative purposes. Many scientific factors must be evaluated when such decisions are being made, but, having made these decisions, it is no less important for the investigator to ensure that the animals selected are also acceptable in terms of health and quality as well as in their scientific suitability. The quality control of vaccines is a statutory requirement which has now been imposed on manufacturers for more than fifty years. The Therapeutic Substances Acts (1925, 1956) and the Diseases of Animals Act (1950) restricted the manufacture of vaccines to holders of licences and laid down, in broad terms, the manner in which vaccines were to be made and the qualities that they must possess. The Medicines Act (1968), which superceded the second Therapeutic Substances Act (1956) and which embraces all pharmaceuticals, continues the licensing system and exerts wide control: (1) Licences to manufacture are issued only after inspection of a manufacturer's facilities (premises, staff and equipment).
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(2) Licences to market are issued only after examination of the proposed methods of manufacture and quality control and after consideration of the safety, efficacy and quality of the product.
(3) Marketing of any vaccine for which there is a monograph in the European or British Pharmacopoeias, the British Pharmaceutical Codex or the British Veterinary Codex is prohibited unless the vaccine complies with the standards of the publication. An inevitable consequence of the provisions of both the earlier legislation and of the Medicines Act was a continuing requirement in the manufacture of almost all vaccines for tests in animals. These were, and remain, tests of two types: 'in process' tests on intermediates during the manufacturing process; and 'pharmacopoeial' tests on the product in its final container. It is not possible, for reasons of commercial confidence, to determine the number of 'in process' controls that are now required in animals during the course of vaccine manufacture, but the number of pharmacopoeial tests can readily be obtained simply by scrutiny of appropriate pharmacopoeial monographs and, as Table 1 shows, these average three per vaccine. A further insight into the extent of this control work on vaccines is provided by the number of animals used for statutory testing in a year, the number for 1975 being 1 188 774. The use of animals on so large a scale clearly requires much justification particularly in times when animal experimentation for any purpose is a matter of much public concern. Fortunately, justification is not hard to find for, despite considerable recent progress with in vitro technology, animals remain the only available indicators of many of the biological activities, both desirable and undesirable, of many vaccine components. Admittedly, some of the tests in animals are very empirical, especially those used to demonstrate the freedom of vaccines from toxicity; others, however, are very specific in character and depend both on the extreme sensitivity of animals to certain biological stimuli and also on the very characteristic physiological and pathological responses that such stimuli evoke.
Consideration of the various tests in animals that are required by the current pharmacopoeial monographs reveals that, although the tests are numerous, all are founded on a limited number of basic techniques. Further, with the exception of a small number of tests undertaken to prove the identity of certain vaccines, all the tests are designed to provide evidence that a vaccine fulfils either a criterion of safety or a criterion of efficacy such as are required by the provisions of the Medicines Act. The various purposes of the tests are shown in Table 2 , but it must be realized that, in practice, the tests are applied only as appropriate in the case of each preparation, with the consequence that, whereas quite simple tests suffice for the testing of some vaccines, very complex tests are needed for others. 
Identity of vaccines
Identity tests for many vaccines can today be performed very expeditiously by in vitro methods but, even so, there remains a small number of preparations for which stimulation of antibody production in vivo still provides the most satisfactory proof of identity. Demonstration of the development of antibody after vaccination of animals may be obtained either by the observation that the animals survive an appropriate challenge or by in vitro testing of sera. In the cases of many vaccines the potency assays involve similar principles and, if performed on vaccine from the final ampoule, serve as effective identity tests.
Safety ofvaccines
Safety is controlled by tests which are designed to reveal qualities of a vaccine which may injure the health or even jeopardize the life of a vaccinee. Such undesirable qualities may be due either to extraneous materials which have accidentally contaminated a vaccine during manufacture, or to vaccine components with intrinsic pathogenicity incompletely eliminated during processing. The forms of the tests reflect the particular hazards associated with each vaccine.
Freedomfrom abnormal toxicity: Extraneous toxic material may, exceptionally, contaminate a vaccine and its presence in dangerous amounts may be excluded by a very simple toxicity test in which two guinea-pigs and five mice are inoculated each with one human dose of vaccine. Survival of the animals in good health for seven days after inoculation is taken as the indicator of innocuity.
Absence ofextraneous pathogens: The animal tissues and sera used for the preparation of cell cultures are both potential sources of extraneous agents, chiefly viruses, which may contaminate the virus fluids from which most virus vaccines are made. Many such agents can be detected in cell culture, but additional assurance of the safety of many vaccines is obtained by inoculation of animals. Typically, guinea-pigs are inoculated intraperitoneally and adult and suckling mice intraperitoneally and intracerebrally, and all are observed for ill effects for periods up to six weeks. Poultry vaccines are inoculated into chicks to exclude the presence of pathogens of poultry.
Freedom from specific toxicity: Diphtheria and tetanus vaccines are prepared from two of the most intensely toxic of all known substances, diphtheria and tetanus toxins, and special tests are needed to ensure that no residual toxin is present in a final product. Guinea-pigs are particularly sensitive to the actions of both toxins and thus both vaccines are tested for residual toxin in this species. The animals are inoculated with five times the human dose and thereafter observed for four weeks for signs of diphtheritic or tetanic toxaemia.
Absence ofinfectivity: Vaccines consisting of suspensions of killed bacteria can always be tested for residual live microbes by classical in vitro methods, and vaccines made of killed virus particles can be tested for residual uninactivated virus in cell culture. Tests in animals, particularly applicable to inactivated poliovaccine and to rabies vaccine produced in cell culture, provide additional assurances of complete inactivation. In the case of killed poliovaccine, cynomologous monkeys, treated with cortisone to increase their sensitivity to infection, are injected with vaccine intramuscularly, intracerebrally and intraspinally, and 17-19 days later are examined clinically for paralysis and histologically for brain and cord lesions indicative of poliovirus infection. In the case of rabies vaccine, intracerebral inoculation of mice and subsequent observation for signs of rabies is the technique used to exclude the presence of residual live virus.
Exclusion of excessive virulence: Vaccines consisting of live microbes of attenuated virulence cannot be considered safe unless tests have excluded the presence of organisms of greater virulence than is normally acceptable. In general, in vitro tests do not provide adequate measures of in vivo virulence, or pathogenicity, and consequently tests in animals are always necessary. In tests of this type animals are inoculated with vaccine by a suitable route and the extent of the lesions which result is examined after the lapse of an appropriate time interval. Thus BCG vaccine is tested by the intramuscular injection of guinea-pigs and subsequent observation of the extent to which the bacteria have spread; Newcastle disease vaccine is given to chickens and is regarded as safe only if none of the chickens develops nervous or respiratory symptoms during the 21 days following vaccination. Live attenuated poliovaccine is, in this respect, of particular interest as the test is required to demonstrate the absence of neurovirulence, a demonstration which is achieved by the intracerebral and intraspinal inoculation of cynomologous monkeys followed by histological examination of the brains and cords for evidence of vaccine-induced histopathology.
The safety test of the British Veterinary Codex (BVC): In the control of vaccines for use in animals it is always possible to conduct laboratory tests in animals of the species in which the vaccine is intended to be used. Thus in the BVC there are many safety tests which require two animals of the appropriate species to be inoculated with a double dose ofvaccine and thereafter observed for ill effects. This test, so obviously impractical for human vaccines, provides ready but nonetheless very convincing evidence of the safety of many veterinary preparations.
Efficacy ofvaccines
Efficacy is measured in terms of immunogenicity. In practice, assays of immunogenicity in which an attempt is made to simulate infection and protection as they occur in natural circumstances are far too cumbersome and expensive for routine use and so, with a single exception in the case of the potency assay for contagious bovine pleuropneumonia vaccine, they are replaced with assays the mechanics of which are highly artificial. However, once it has been demonstrated that the results of such tests correlate well with results obtained under field conditions, the tests are acceptable measures of immunogenicity and have the advantage that they are easily regulated in the laboratory and provide results suitable for statistical evaluation. Furthermore, such tests can often be conducted in ways which are more humane than methods involving natural infection.
The potency assayfor contagious bovine pleuropneumonia vaccine: In this assay a small herd of cattle is divided into two halves, one half being inoculated and the other left as controls. Animals infected with contagious bovine pleuropneumonia are subsequently introduced into the herd and an estimate of the efficacy of the vaccine is obtained from a comparison of the numbers of inoculated and uninoculated animals which become infected.
'Pass or fail' assays and 3 +3 quantal assays: The simplest tests of immunogenicity are those that involve the immunization of a small group of animals (10 or 12) with vaccine at a single dose level followed by challenge with the agent against which the vaccine is intended to provide protection or, alternatively, measurement of the antibody appearing in the animals' sera.
Vaccines are considered to pass such tests if an arbitrary proportion of the animals is protected from the challenge or an arbitrary mean level of antibody is evoked. Such 'pass or fail' tests, however, can very readily provide different results in different experimental circumstances, as they are, by their very format, completely uncontrolled. As a consequence of such irregularities, statistically-based assays are now being increasingly adopted. The 3 + 3 quantal assay technique, in which three groups of animals are immunized each with one of three concentrations of a standard vaccine, and three groups are immunized each with one of three concentrations of the test vaccine prior to subsequent challenge with the appropriate pathogen, has long been used for the potency assay of whooping-cough vaccine and is soon to be required by the European Pharmacopoeia for that of absorbed diphtheria and tetanus vaccines. This form of assay has great advantages over the 'pass or fail' type of test, in that comparison of the percentages of survivors in the groups of animals by the technique of probit analysis provides not only an. estimate of the potency of the test vaccine in terms of the standard but, in addition, the confidence limits of that estimate.
Assay ofsensitizing potency: Lastly, and uniquely in the quality control of BCG vaccine, is the use of animals to demonstrate the development of immunity through the mediation of delayed hypersensitivity. In this test, BCG-vaccinated guinea-pigs are challenged with an intradermal dose of tuberculin and the development of a reaction of delayed hypersensitivity, a Mantoux type reaction, is observed 24 hours later. Development of the reaction is indicative of a vaccine of adequate potency.
Taken together the tests in animals used in the quality control of vaccines serve many purposes for which there are at present no acceptable alternatives and, although the number of basic procedures is quite small, adaptations of these to the circumstances of individual vaccines can provide very firm assurances of the identity, the safety, and the efficacy of most vaccines. About a century ago George Eliot caused one of her characters to observe that 'animals are such agreeable friends, they ask no questions. . .' If she were writing today she might well extend that observation by adding that they nevertheless provide many answers.
